KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer
Sands, J. Reck, M. Navarro, A. Chiang, A. C. Lu, S. Peled, N. Paz-Ares, L. G. Kerr, S. J. Takahashi, T. Smolin, A.
Sands, J.
Reck, M.
Navarro, A.
Chiang, A. C.
Lu, S.
Peled, N.
Paz-Ares, L. G.
Kerr, S. J.
Takahashi, T.
Smolin, A.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Sands J, Reck M, Navarro A, Chiang AC, Lu S, Peled N, et al. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680305119.